Switch to
More onapp

Alembic Pharmaceuticals Ltd

APLLTD
Health CarePharmaceuticals
SmallcapWith a market cap of ₹11,794 cr, stock is ranked 316
Low RiskStock is 1.45x as volatile as Nifty
597.602.45 (-0.41%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹11,794 cr, stock is ranked 316
Low RiskStock is 1.45x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
22.64
PB RatioPB Ratio
2.25
Dividend YieldDiv. Yield
1.67%
Sector PESector PE
35.92
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

28%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Alembic Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company focuses on anti-infective, analgesic and, cough and cold therapies. It also focuses on therapies, such as cardiology, diabetes, gynecology, gastrointestinal, orthopedic, dermatology and ophthalmology. Its APIs include independent manufacturing blocks for Macrolides, non-steroidal anti-inflammatory drugs (NSAIDs) and other drugs. The Company offers international and domestic formulations. Under domestic formulation, it offers Branded Formulations and Generic formulations. Its domestic formulation include Roxid, Zofix, Althrocin, Tellzy AH, Revas H, Lactonic, Folinal, Gestofit, Glisen 1/2, Glimser 1/2, Veldrop, Azithral, Brinzemic and Neolap. Its generic formulations include Cetral, Ephedrex CD, Sicor, Worid, Alcephin, Alcizon, Baciclox, Comeba, Furobid, O Win Suspension, O win T, Silomag Gel, Pentab, Aginal AT and Pyremol.

Financial TrendFinancial statements 

20192020202120223.944.615.485.360.580.831.150.52
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Loss of share certificate 
Announced OnNov 25, 2022

Alembic Pharmaceuticals Limited has informed the Exchange about Issue of Duplicate Share Certificates/Letter of Confirmation. | Download

Alembic Pharmaceuticals Limited has informed the Exchange about Issue of Duplicate Share Certificates/Letter of Confirmation. | Download

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 25, 2022

Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Cash Dividend 
Ex. DateAug 17, 2022

Interim • Div/Share: ₹ 10

See all events